-
Je něco špatně v tomto záznamu ?
International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study
WR. Sperr, M. Kundi, I. Alvarez-Twose, B. van Anrooij, JNG. Oude Elberink, A. Gorska, M. Niedoszytko, KV. Gleixner, E. Hadzijusufovic, R. Zanotti, P. Bonadonna, M. Bonifacio, C. Perkins, A. Illerhaus, C. Elena, S. Merante, K. Shoumariyeh, N. von...
Jazyk angličtina Země Velká Británie
Typ dokumentu časopisecké články
- MeSH
- analýza přežití MeSH
- dospělí MeSH
- internacionalita MeSH
- kohortové studie MeSH
- lidé středního věku MeSH
- lidé MeSH
- mastocytóza diagnóza mortalita MeSH
- mladiství MeSH
- mladý dospělý MeSH
- prognóza MeSH
- registrace MeSH
- retrospektivní studie MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- Světová zdravotnická organizace MeSH
- výzkumný projekt MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- Geografické názvy
- Španělsko MeSH
BACKGROUND: The WHO classification separates mastocytosis into distinct variants, but prognostication remains a clinical challenge. The aim of this study was to improve prognostication for patients with mastocytosis. METHODS: We analysed data of the registry of the European Competence Network on Mastocytosis including 1639 patients (age 17-90 years) diagnosed with mastocytosis according to WHO criteria between Jan 12, 1978, and March 16, 2017. Univariate and multivariate analyses with Cox regression were applied to identify prognostic variables predicting survival outcomes and to establish a prognostic score. We validated this International Prognostic Scoring System in Mastocytosis (IPSM) with data of 462 patients (age 17-79 years) from the Spanish network Red Española de Mastocitosis diagnosed between Jan 22, 1998, and Nov 2, 2017. FINDINGS: The prognostic value of the WHO classification was confirmed in our study (p<0·0001). For patients with non-advanced mastocytosis (n=1380), we identified age 60 years or older (HR 10·75, 95% CI 5·68-20·32) and a concentration of alkaline phosphatase 100 U/L or higher (2·91, 1·60-5·30) as additional independent prognostic variables for overall survival. The resulting scoring system divided patients with non-advanced mastocytosis into three groups: low (no risk factors), intermediate 1 (one risk factor), and intermediate 2 (two risk factors). Overall survival and progression-free survival differed significantly among these groups (p<0·0001). In patients with advanced mastocytosis (n=259), age 60 years or older (HR 2·14, 95% CI 1·42-3·22), a concentration of tryptase 125 ng/mL or higher (1·81, 1·20-2·75), a leukocyte count of 16 × 109 per L or higher (1·88, 1·27-2·79), haemoglobin of 11 g/dL or lower (1·71, 1·13-2·57), a platelet count of 100 × 109 per L or lower (1·63, 1·13-2·34), and skin involvement (0·46, 0·30-0·69) were prognostic variables. Based on these variables, a separate score for advanced mastocytosis with four risk categories was established, with significantly different outcomes for overall survival and progression-free survival (p<0·0001). The prognostic value of both scores was confirmed in 413 patients with non-advanced disease and 49 with advanced mastocytosis from the validation cohort. INTERPRETATION: The IPSM scores for patients with non-advanced and advanced mastocytosis can be used to predict survival outcomes and guide treatment decisions. However, the predictive value of the IPSM needs to be confirmed in forthcoming trials. FUNDING: Austrian Science Fund, Deutsche Forschungsgemeinschaft, Koeln Fortune Program, Charles and Ann Johnson Foundation, Instituto de Salud Carlos III, Fondos FEDER, Research-Foundation Flanders/Fonds Wetenschappelijk Onderzoek, Clinical Research-Fund of the University Hospitals Leuven, and Research-Foundation Flanders/Fonds Wetenschappelijk Onderzoek.
3 Medizinische Klinik Universitätsmedizin Mannheim Universität Heidelberg Mannheim Germany
Allergy Unit Verona University Hospital Verona Italy
Department of Allergology Medical University of Gdańsk Gdańsk Poland
Department of Dermatology and Venereology University Hospital Graz Graz Austria
Department of Dermatology Medical University of Gdańsk Gdańsk Poland
Department of Dermatology University of Cologne Cologne Germany
Division of Allergy and Clinical Immunology University of Salerno Salerno Italy
Division of Hematology Department of Medical Sciences Uppsala University Uppsala Sweden
Division of Hematology Department of Medicine Stanford University School of Medicine Stanford CA USA
Division of Hematology Istanbul Medical School University of Istanbul Istanbul Turkey
Institute of Environmental Health Medical University of Vienna Vienna Austria
Instituto de Estudios de Mastocitosis de Castilla La Mancha Hospital Virgen del Valle Toledo Spain
Pediatric Dermatology Unit Department of Medicine University of Padua Padua Italy
Section of Hematology Department of Medicine Verona University Hospital Verona Italy
University Hospital and CEITEC Masaryk University Brno Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19044497
- 003
- CZ-PrNML
- 005
- 20200120100834.0
- 007
- ta
- 008
- 200109s2019 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/S2352-3026(19)30166-8 $2 doi
- 035 __
- $a (PubMed)31676322
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Sperr, Wolfgang R $u Department of Internal Medicine I, Division of Hematology and Hemostaseology, and Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria. Electronic address: wolfgang.r.sperr@meduniwien.ac.at.
- 245 10
- $a International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study / $c WR. Sperr, M. Kundi, I. Alvarez-Twose, B. van Anrooij, JNG. Oude Elberink, A. Gorska, M. Niedoszytko, KV. Gleixner, E. Hadzijusufovic, R. Zanotti, P. Bonadonna, M. Bonifacio, C. Perkins, A. Illerhaus, C. Elena, S. Merante, K. Shoumariyeh, N. von Bubnoff, R. Parente, M. Jawhar, A. Belloni Fortina, F. Caroppo, K. Brockow, A. Zink, D. Fuchs, AJ. Kilbertus, AS. Yavuz, M. Doubek, H. Hägglund, J. Panse, V. Sabato, A. Bretterklieber, D. Niederwieser, C. Breynaert, K. Hartmann, M. Triggiani, B. Nedoszytko, A. Reiter, A. Orfao, O. Hermine, J. Gotlib, M. Arock, HC. Kluin-Nelemans, P. Valent,
- 520 9_
- $a BACKGROUND: The WHO classification separates mastocytosis into distinct variants, but prognostication remains a clinical challenge. The aim of this study was to improve prognostication for patients with mastocytosis. METHODS: We analysed data of the registry of the European Competence Network on Mastocytosis including 1639 patients (age 17-90 years) diagnosed with mastocytosis according to WHO criteria between Jan 12, 1978, and March 16, 2017. Univariate and multivariate analyses with Cox regression were applied to identify prognostic variables predicting survival outcomes and to establish a prognostic score. We validated this International Prognostic Scoring System in Mastocytosis (IPSM) with data of 462 patients (age 17-79 years) from the Spanish network Red Española de Mastocitosis diagnosed between Jan 22, 1998, and Nov 2, 2017. FINDINGS: The prognostic value of the WHO classification was confirmed in our study (p<0·0001). For patients with non-advanced mastocytosis (n=1380), we identified age 60 years or older (HR 10·75, 95% CI 5·68-20·32) and a concentration of alkaline phosphatase 100 U/L or higher (2·91, 1·60-5·30) as additional independent prognostic variables for overall survival. The resulting scoring system divided patients with non-advanced mastocytosis into three groups: low (no risk factors), intermediate 1 (one risk factor), and intermediate 2 (two risk factors). Overall survival and progression-free survival differed significantly among these groups (p<0·0001). In patients with advanced mastocytosis (n=259), age 60 years or older (HR 2·14, 95% CI 1·42-3·22), a concentration of tryptase 125 ng/mL or higher (1·81, 1·20-2·75), a leukocyte count of 16 × 109 per L or higher (1·88, 1·27-2·79), haemoglobin of 11 g/dL or lower (1·71, 1·13-2·57), a platelet count of 100 × 109 per L or lower (1·63, 1·13-2·34), and skin involvement (0·46, 0·30-0·69) were prognostic variables. Based on these variables, a separate score for advanced mastocytosis with four risk categories was established, with significantly different outcomes for overall survival and progression-free survival (p<0·0001). The prognostic value of both scores was confirmed in 413 patients with non-advanced disease and 49 with advanced mastocytosis from the validation cohort. INTERPRETATION: The IPSM scores for patients with non-advanced and advanced mastocytosis can be used to predict survival outcomes and guide treatment decisions. However, the predictive value of the IPSM needs to be confirmed in forthcoming trials. FUNDING: Austrian Science Fund, Deutsche Forschungsgemeinschaft, Koeln Fortune Program, Charles and Ann Johnson Foundation, Instituto de Salud Carlos III, Fondos FEDER, Research-Foundation Flanders/Fonds Wetenschappelijk Onderzoek, Clinical Research-Fund of the University Hospitals Leuven, and Research-Foundation Flanders/Fonds Wetenschappelijk Onderzoek.
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a kohortové studie $7 D015331
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a internacionalita $7 D038622
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a mastocytóza $x diagnóza $x mortalita $7 D008415
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a registrace $7 D012042
- 650 _2
- $a výzkumný projekt $7 D012107
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a analýza přežití $7 D016019
- 650 _2
- $a Světová zdravotnická organizace $7 D014944
- 650 _2
- $a mladý dospělý $7 D055815
- 651 _2
- $a Španělsko $x epidemiologie $7 D013030
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Kundi, Michael $u Institute of Environmental Health, Medical University of Vienna, Vienna, Austria.
- 700 1_
- $a Alvarez-Twose, Ivan $u Instituto de Estudios de Mastocitosis de Castilla La Mancha (CLMast), Hospital Virgen del Valle, Toledo, Spain.
- 700 1_
- $a van Anrooij, Bjorn $u Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands; Department of Allergology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands.
- 700 1_
- $a Oude Elberink, Joanna N G $u Department of Allergology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands.
- 700 1_
- $a Gorska, Aleksandra $u Department of Allergology, Medical University of Gdańsk, Gdańsk, Poland.
- 700 1_
- $a Niedoszytko, Marek $u Department of Allergology, Medical University of Gdańsk, Gdańsk, Poland.
- 700 1_
- $a Gleixner, Karoline V $u Department of Internal Medicine I, Division of Hematology and Hemostaseology, and Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria.
- 700 1_
- $a Hadzijusufovic, Emir $u Department of Internal Medicine I, Division of Hematology and Hemostaseology, and Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria; Internal Medicine Small Animals, University Clinic for Small Animals, Department/University Clinic for Companion Animals and Horses, University of Veterinary Medicine, Vienna, Austria.
- 700 1_
- $a Zanotti, Roberta $u Section of Hematology, Department of Medicine, Verona University Hospital, Verona, Italy.
- 700 1_
- $a Bonadonna, Patrizia $u Allergy Unit, Verona University Hospital, Verona, Italy.
- 700 1_
- $a Bonifacio, Massimiliano $u Section of Hematology, Department of Medicine, Verona University Hospital, Verona, Italy.
- 700 1_
- $a Perkins, Cecelia $u Division of Hematology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
- 700 1_
- $a Illerhaus, Anja $u Department of Dermatology, University of Cologne, Cologne, Germany.
- 700 1_
- $a Elena, Chiara $u Department of Molecular Medicine and Department of Hematology Oncology, University of Pavia and Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
- 700 1_
- $a Merante, Serena $u Department of Molecular Medicine and Department of Hematology Oncology, University of Pavia and Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
- 700 1_
- $a Shoumariyeh, Khalid $u Department of Hematology, Oncology and Stem Cell Transplantation, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
- 700 1_
- $a von Bubnoff, Nikolas $u Department of Hematology, Oncology and Stem Cell Transplantation, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany; Department of Hematology and Oncology, Medical Center, University of Schleswig-Holstein, Campus Lübeck, Lübeck, Germany.
- 700 1_
- $a Parente, Roberta $u Division of Allergy and Clinical Immunology, University of Salerno, Salerno, Italy.
- 700 1_
- $a Jawhar, Mohamad $u III Medizinische Klinik, Universitätsmedizin Mannheim, Universität Heidelberg, Mannheim, Germany.
- 700 1_
- $a Belloni Fortina, Anna $u Pediatric Dermatology Unit, Department of Medicine, University of Padua, Padua, Italy.
- 700 1_
- $a Caroppo, Francesca $u Pediatric Dermatology Unit, Department of Medicine, University of Padua, Padua, Italy.
- 700 1_
- $a Brockow, Knut $u Department of Dermatology and Allergy, School of Medicine, Technical University of Munich, Munich, Germany.
- 700 1_
- $a Zink, Alexander $u Department of Dermatology and Allergy, School of Medicine, Technical University of Munich, Munich, Germany.
- 700 1_
- $a Fuchs, David $u University Clinic for Hematology and Internal Oncology, Kepler University Hospital, Johannes Kepler University, Linz, Austria.
- 700 1_
- $a Kilbertus, Alex J $u Department of Dermatology and Venerology, Kepler University Hospital, Johannes Kepler University, Linz, Austria.
- 700 1_
- $a Yavuz, Akif Selim $u Division of Hematology, Istanbul Medical School, University of Istanbul, Istanbul, Turkey.
- 700 1_
- $a Doubek, Michael $u University Hospital and CEITEC Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Hägglund, Hans $u Division of Hematology, Department of Medical Sciences Uppsala University, Uppsala, Sweden.
- 700 1_
- $a Panse, Jens $u Department of Oncology, Haematology, Haemostaseology and Stem Cell Transplantation, University Hospital RWTH Aachen, Aachen, Germany.
- 700 1_
- $a Sabato, Vito $u Faculty of Medicine and Health Sciences, Department of Immunology-Allergology-Rheumatology, University of Antwerp and Antwerp University Hospital, Antwerp, Belgium.
- 700 1_
- $a Bretterklieber, Agnes $u Department of Dermatology and Venereology, University Hospital Graz, Graz, Austria.
- 700 1_
- $a Niederwieser, Dietger $u University Hospital of Leipzig, Leipzig, Germany.
- 700 1_
- $a Breynaert, Christine $u KU Leuven Department of Microbiology, Immunology and Transplantation, Allergy and Clinical Immunology Research Group and MASTeL, University Hospitals Leuven, Leuven, Belgium.
- 700 1_
- $a Hartmann, Karin $u Department of Dermatology, University of Cologne, Cologne, Germany; Division of Allergy, Department of Dermatology, and Department of Biomedicine, University of Basel, Basel, Switzerland.
- 700 1_
- $a Triggiani, Massimo $u Division of Allergy and Clinical Immunology, University of Salerno, Salerno, Italy.
- 700 1_
- $a Nedoszytko, Boguslaw $u Department of Dermatology, Medical University of Gdańsk, Gdańsk, Poland.
- 700 1_
- $a Reiter, Andreas $u III Medizinische Klinik, Universitätsmedizin Mannheim, Universität Heidelberg, Mannheim, Germany.
- 700 1_
- $a Orfao, Alberto $u Centro de Investigación del Cáncer/IBMCC (USAL/CSIC), CIBERONC and IBSAL, Departamento de Medicina and Servicio General de Citometría, University of Salamanca, Salamanca, Spain.
- 700 1_
- $a Hermine, Olivier $u Imagine Institute Université Paris Descartes, Sorbonne, Paris Cité, Centre national de référence des mastocytoses, Paris, France.
- 700 1_
- $a Gotlib, Jason $u Division of Hematology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
- 700 1_
- $a Arock, Michel $u Department of Hematological Biologie, Pitié-Salpêtrière Hospital, Paris Sorbonne University, Paris UMR8113, Ecole, France.
- 700 1_
- $a Kluin-Nelemans, Hanneke C $u Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands.
- 700 1_
- $a Valent, Peter $u Department of Internal Medicine I, Division of Hematology and Hemostaseology, and Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria.
- 773 0_
- $w MED00193479 $t The Lancet. Haematology $x 2352-3026 $g Roč. 6, č. 12 (2019), s. e638-e649
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31676322 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20200109 $b ABA008
- 991 __
- $a 20200120101210 $b ABA008
- 999 __
- $a ok $b bmc $g 1482766 $s 1083170
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 6 $c 12 $d e638-e649 $e 20191031 $i 2352-3026 $m The Lancet. Haematology $n Lancet Haematol $x MED00193479
- LZP __
- $a Pubmed-20200109
